Drugs A-Z Is my price fair? Price changes Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Generic drug

Liraglutide price, strengths & recalls

Generic of Victoza, Saxenda

Pharmacies pay $257.25 for 9 mL of Liraglutide 6 mg/mL, 3 mL pen this week, and from $257.25 to $709.00 across its 2 priced strengths and forms. 11 manufacturers make it. It is in shortage (limited availability). 1 recall is ongoing. Its official label last changed on November 2, 2026.

Limited availability1 open recallGeneric
Pharmacies pay$257.25for 9 mL of 6 mg/mL, 3 mL pen-6.7% in 4 weeks
Fair cash price
$306.34
Strengths
2
Makers
11
Updated
Nov 11

Liraglutide price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
6 mg/mL pen$47.27$709.00 / 15 mL-4.0%
6 mg/mL, 3 mL pen$28.58$257.25 / 9 mL-6.7%-46.4%

Brand names of liraglutide

A brand and its generic share the active ingredient; the generic is almost always far cheaper.

Supply status: shortages & recalls

In shortage10 products are short or being discontinued
1 ongoing recall3 recalls on record, latest May 27, 2026

Shortages

  • Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)Hikma Pharmaceuticals USA, Inc. · Available · Updated Oct 14, 2026
  • Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)Hikma Pharmaceuticals USA, Inc. · Available · Updated Oct 14, 2026
  • Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)Novo Nordisk, Inc. · Limited Availability · Reason: Delay in shipping of the drug · Updated Sep 22, 2026Estimated shortage duration: TBD
  • Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)Novo Nordisk, Inc. · Available · Updated Sep 22, 2026Distributed by Teva
  • Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)Novo Nordisk, Inc. · Limited Availability · Reason: Delay in shipping of the drug · Updated Sep 22, 2026Estimated shortage duration: TBD
  • Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)Novo Nordisk, Inc. · Available · Updated Sep 22, 2026Distributed by Teva
  • Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)Meitheal Pharmaceuticals, Inc. · Available · Updated Aug 27, 2026
  • Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)Meitheal Pharmaceuticals, Inc. · Available · Updated Aug 27, 2026
  • Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)Novo Nordisk, Inc. · Being discontinued Aug 25, 2026 · Updated Aug 25, 2026Product will be available until discontinuation in January 2027; Discontinuation of the manufacture of the drug
  • Liraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46)Teva Pharmaceuticals USA, Inc. · Being discontinued May 14, 2026 · Updated May 14, 2026Discontinuation of the manufacture of the drug

In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.

Recalls

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

What did you pay for liraglutide? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedNovember 2, 2026
Version11 of 4
EffectiveOct 30, 2026
Read the label

These highlights do not include all the information needed to use LIRAGLUTIDE INJECTION safely and effectively. See full prescribing information for LIRAGLUTIDE INJECTION.LIRAGLUTIDE injection, for subcutaneous useInitial U.S. Approval: 2010

This drug has a boxed warning

WARNING: RISK OF THYROID C-CELL TUMORS

WARNING: RISK OF THYROID C-CELL TUMORS

Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether liraglutide injection causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions (5.1), Nonclinical Toxicology (13.1)].

Liraglutide injection is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of liraglutide injection and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with liraglutide injection [see Contraindications (4), Warnings and Precautions (5.1)].

WARNING: RISK OF THYROID C-CELL TUMORS

See full prescribing information for complete boxed warning.

• Liraglutide causes thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It is unknown whether liraglutide injection causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined (5.1, 13.1).

• Liraglutide injection is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and the symptoms of thyroid tumors (4, 5.1).

Recent major changes (as listed on the label)

RECENT MAJOR CHANGES

Indications and Usage. . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . 05/2025

Warnings and Precautions

Severe Gastrointestinal Adverse Reactions (5.6) . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . .. . . . . 10/2025

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Application
NDA022341 · Novo Nordisk Inc
First approved
January 25, 2010 (16 years ago)
Latest approved change
October 14, 2025
Approved label
PDF, Oct 15, 2025
Generic makers
8 approved generic applications on the market
Last patent listed
July 9, 2037

Liraglutide questions

How much does liraglutide cost without insurance?

Pharmacies pay about $257.25 for 9 mL of liraglutide 6 mg/mL, 3 mL pen ($28.58 per mL). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $306.34. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

What is the brand name of liraglutide?

Liraglutide is sold as Victoza, Saxenda. The generic has the same active ingredient and usually costs far less.

Is liraglutide in shortage?

Yes. 10 products are listed as in shortage or being discontinued (limited availability). See which ones.

Has liraglutide been recalled?

3 recalls on record, 1 ongoing. Recalls name specific lots - check yours.

When did the liraglutide label last change?

The official label was last updated on November 2, 2026 (version 11). See what changed.

Talk about liraglutide

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.